Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

abstract：:Tumor-infiltrating lymphocytes (TIL) in colorectal cancer liver metastases (CLM) have been associated with more favorable patient outcomes, but whether MHC class I (MHC-I) expression on cancer cells affects prognosis is uncertain. Immunohistochemistry was performed on a tissue microarray of 158 patients with CLM, who ...

journal_title：Cancer immunology research

authors： Turcotte S,Katz SC,Shia J,Jarnagin WR,Kingham TP,Allen PJ,Fong Y,D'Angelica MI,DeMatteo RP

更新日期：2014-06-01 00:00:00

abstract：:Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non-clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we e...

journal_title：Cancer immunology research

authors： McKay RR,Bossé D,Xie W,Wankowicz SAM,Flaifel A,Brandao R,Lalani AA,Martini DJ,Wei XX,Braun DA,Van Allen E,Castellano D,De Velasco G,Wells JC,Heng DY,Fay AP,Schutz FA,Hsu J,Pal SK,Lee JL,Hsieh JJ,Harshman LC,Si

更新日期：2018-07-01 00:00:00

abstract：:Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable successes in fighting B-cell leukemias/lymphomas. Promising response rates are reported in patients treated with B-cell maturation antigen (BCMA) CAR T cells for multiple myeloma. However, responses appear to be nondurable, highlighting the need to ex...

journal_title：Cancer immunology research

authors： Globerson Levin A,Rawet Slobodkin M,Waks T,Horn G,Ninio-Many L,Deshet Unger N,Ohayon Y,Suliman S,Cohen Y,Tartakovsky B,Naparstek E,Avivi I,Eshhar Z

更新日期：2020-12-01 00:00:00

abstract：:Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with ago...

journal_title：Cancer immunology research

authors： Wiehagen KR,Girgis NM,Yamada DH,Smith AA,Chan SR,Grewal IS,Quigley M,Verona RI

更新日期：2017-12-01 00:00:00

abstract：:Inciting the cellular arm of adaptive immunity has been the fundamental goal of cancer immunotherapy strategies, specifically focusing on inducing tumor antigen-specific responses by CD8(+) cytotoxic T lymphocytes (CTL). However, there is an emerging appreciation that the cytotoxic function of CD4(+) T cells can be ef...

journal_title：Cancer immunology research

authors： Nelles ME,Moreau JM,Furlonger CL,Berger A,Medin JA,Paige CJ

更新日期：2014-11-01 00:00:00

abstract：:We conducted in vitro studies and a clinical trial for patients with squamous cell carcinoma of the head and neck (SCCHN) to study the relationship between FcγRIIIa polymorphisms and antibody-dependent cellular cytotoxicity (ADCC). In vitro, FcγRIIIa genotype was correlated with ADCC and innate cytotoxicity using natu...

journal_title：Cancer immunology research

authors： Taylor RJ,Saloura V,Jain A,Goloubeva O,Wong S,Kronsberg S,Nagilla M,Silpino L,de Souza J,Seiwert T,Vokes E,Villaflor V,Cohen EE

更新日期：2015-05-01 00:00:00

abstract：:Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

journal_title：Cancer immunology research

authors： Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

更新日期：2014-07-01 00:00:00

abstract：:SLAMF6, a member of the SLAM (signaling lymphocyte activation molecules) family, is a homotypic-binding immune receptor expressed on NK, T, and B lymphocytes. Phosphorylation variance between T-cell subclones prompted us to explore its role in anti melanoma immunity. Using a 203-amino acid sequence of the human SLAMF6...

journal_title：Cancer immunology research

authors： Eisenberg G,Engelstein R,Geiger-Maor A,Hajaj E,Merims S,Frankenburg S,Uzana R,Rutenberg A,Machlenkin A,Frei G,Peretz T,Lotem M

更新日期：2018-02-01 00:00:00

abstract：:Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that phenotypically resemble conventional secondary lymphoid organs and are commonly found at sites of chronic inflammation. They are also found in a wide variety of primary and metastatic human tumors. The presence of tumor-associated TLS (TA-TLS) is ...

journal_title：Cancer immunology research

authors： Rodriguez AB,Engelhard VH

更新日期：2020-11-01 00:00:00

abstract：:Ipilimumab, a novel immune checkpoint inhibitor, is associated with long-term survival in approximately 20% of patients with advanced melanoma and is also being evaluated in the adjuvant setting. With this growing cohort of survivors, long-term health outcomes, chronic toxicities, and functional outcomes among survivo...

journal_title：Cancer immunology research

authors： Johnson DB,Friedman DL,Berry E,Decker I,Ye F,Zhao S,Morgans AK,Puzanov I,Sosman JA,Lovly CM

更新日期：2015-05-01 00:00:00

abstract：:With the advancement of personalized cancer immunotherapies, new tools are needed to identify tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit clinically relevant tumor progression. Key transgenic mouse models of breast cancer are generated and maintained on the FVB geneti...

journal_title：Cancer immunology research

authors： DeVette CI,Andreatta M,Bardet W,Cate SJ,Jurtz VI,Jackson KW,Welm AL,Nielsen M,Hildebrand WH

更新日期：2018-06-01 00:00:00

abstract：:Cancer-testis (CT) antigens are attractive tumor antigens for cancer immunotherapy. They comprise a group of proteins normally expressed in germ cells and aberrantly activated in a variety of human cancers. The protein expression of eight cancer-testis antigens [MAGEA, NY-ESO-1, GAGE, MAGEC1 (CT7), MAGEC2 (CT10), CT45...

journal_title：Cancer immunology research

authors： Chen YT,Panarelli NC,Piotti KC,Yantiss RK

更新日期：2014-05-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF...

journal_title：Cancer immunology research

authors： Jhaveri DT,Kim MS,Thompson ED,Huang L,Sharma R,Klein AP,Zheng L,Le DT,Laheru DA,Pandey A,Jaffee EM,Anders RA

更新日期：2016-03-01 00:00:00

abstract：:Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical benefits in treatment of established tumors have remained modest. Several immune evasion mechanisms hinder T-cell entry into tumors and their activity within the tumor. Of note, oncolytic adenoviruses are intrinsically immun...

journal_title：Cancer immunology research

authors： Tähtinen S,Grönberg-Vähä-Koskela S,Lumen D,Merisalo-Soikkeli M,Siurala M,Airaksinen AJ,Vähä-Koskela M,Hemminki A

更新日期：2015-08-01 00:00:00

abstract：:Regulatory T cells (Treg) have long been considered one-sided suppressors of antitumor immune responses and hence associated with poor patient outcome in cancer. However, evidence is mounting of a paradoxical positive prognostic effect of Tregs on certain malignancies, including urinary bladder cancer (UBC). This disc...

journal_title：Cancer immunology research

authors： Winerdal ME,Krantz D,Hartana CA,Zirakzadeh AA,Linton L,Bergman EA,Rosenblatt R,Vasko J,Alamdari F,Hansson J,Holmström B,Johansson M,Winerdal M,Marits P,Sherif A,Winqvist O

更新日期：2018-05-01 00:00:00

abstract：:The current standard of care for treatment of metastatic renal cell carcinoma (mRCC) patients is PD-1/PD-L1 inhibitors until progression or toxicity. Here, we characterize the clinical outcomes for 19 mRCC patients who experienced an initial clinical response (any degree of tumor shrinkage), but after immune-related a...

journal_title：Cancer immunology research

authors： Martini DJ,Hamieh L,McKay RR,Harshman LC,Brandao R,Norton CK,Steinharter JA,Krajewski KM,Gao X,Schutz FA,McGregor B,Bossé D,Lalani AA,De Velasco G,Michaelson MD,McDermott DF,Choueiri TK

更新日期：2018-04-01 00:00:00

abstract：:Many immunotherapeutic approaches under development rely on T-cell recognition of cancer-derived peptides bound to human leukocyte antigen molecules on the cell surface. Direct experimental demonstration that such peptides are processed and bound is currently challenging. Here, we describe a method that meets this cha...

journal_title：Cancer immunology research

authors： Wang Q,Douglass J,Hwang MS,Hsiue EH,Mog BJ,Zhang M,Papadopoulos N,Kinzler KW,Zhou S,Vogelstein B

更新日期：2019-11-01 00:00:00

abstract：:Individuals of African descent are disproportionately affected by specific complex diseases, such as breast and prostate cancer, which are driven by both biological and nonbiological factors. In the case of breast cancer, there is clear evidence that psychosocial factors (environment, socioeconomic status, health beha...

journal_title：Cancer immunology research

authors： Yeyeodu ST,Kidd LR,Kimbro KS

更新日期：2019-09-01 00:00:00

abstract：:Vaccinia virus (VACV) is a double-stranded DNA virus that devotes a large portion of its 200 kbp genome to suppressing and manipulating the immune response of its host. Here, we investigated how targeted removal of immunomodulatory genes from the VACV genome impacted immune cells in the tumor microenvironment with the...

journal_title：Cancer immunology research

authors： Umer BA,Noyce RS,Franczak BC,Shenouda MM,Kelly RG,Favis NA,Desaulniers M,Baldwin TA,Hitt MM,Evans DH

更新日期：2020-05-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8+ T cells and resistance to immunotherapeutic interventions. Cancer-associated mechanisms that elicit CD8+ T-cell exclusion and resistance to immunotherapy are not well-known. Here, using a Kras- and p53-...

journal_title：Cancer immunology research

authors： Mirlekar B,Michaud D,Lee SJ,Kren NP,Harris C,Greene K,Goldman EC,Gupta GP,Fields RC,Hawkins WG,DeNardo DG,Rashid NU,Yeh JJ,McRee AJ,Vincent BG,Vignali DAA,Pylayeva-Gupta Y

更新日期：2020-03-01 00:00:00

abstract：:High levels of human telomerase reverse transcriptase (hTERT) are detected in more than 85% of human cancers. Immunologic analysis supports that hTERT is a widely applicable target recognized by T cells and can be potentially studied as a broad cancer immunotherapeutic, or a unique line of defense against tumor recurr...

journal_title：Cancer immunology research

authors： Yan J,Pankhong P,Shin TH,Obeng-Adjei N,Morrow MP,Walters JN,Khan AS,Sardesai NY,Weiner DB

更新日期：2013-09-01 00:00:00

abstract：:Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK-cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield useful biomarkers for...

journal_title：Cancer immunology research

authors： Du J,Lopez-Verges S,Pitcher BN,Johnson J,Jung SH,Zhou L,Hsu K,Czuczman MS,Cheson B,Kaplan L,Lanier LL,Venstrom JM

更新日期：2014-09-01 00:00:00

abstract：:The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signal...

journal_title：Cancer immunology research

authors： Srivastava RM,Trivedi S,Concha-Benavente F,Hyun-Bae J,Wang L,Seethala RR,Branstetter BF 4th,Ferrone S,Ferris RL

更新日期：2015-08-01 00:00:00

abstract：:Granulocytic-macrophage colony-stimulating factor (GM-CSF) is used as an adjuvant in cancer vaccine trials and has the potential to enhance antitumor efficacy with immunotherapy; however, its immunologic effects are not fully understood. Here, we report results from a phase I study of neoadjuvant GM-CSF in patients wi...

journal_title：Cancer immunology research

authors： Wei XX,Chan S,Kwek S,Lewis J,Dao V,Zhang L,Cooperberg MR,Ryan CJ,Lin AM,Friedlander TW,Rini B,Kane C,Simko JP,Carroll PR,Small EJ,Fong L

更新日期：2016-11-01 00:00:00

abstract：:Anti-Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical activity of anti-PD-1 nor the incidence of an immunoresponsive tumor microenvironment has been described for GCTs. A patient ...

journal_title：Cancer immunology research

authors： Shah S,Ward JE,Bao R,Hall CR,Brockstein BE,Luke JJ

更新日期：2016-11-01 00:00:00

abstract：:Activation of YAP, a Hippo pathway effector, is an important resistance mechanism to BRAF inhibitor (BRAFi) in melanoma. Emerging evidence also suggests that YAP is involved in suppression of the antitumor immune response. However, the potential direct impact of YAP activity on cytotoxic T-cell immune responses has no...

journal_title：Cancer immunology research

authors： Kim MH,Kim CG,Kim SK,Shin SJ,Choe EA,Park SH,Shin EC,Kim J

更新日期：2018-03-01 00:00:00

abstract：:Pancreatic cancer is a devastating disease that is largely refractory to currently available treatment strategies. Therapeutic resistance is partially attributed to the dense stromal reaction of pancreatic ductal adenocarcinoma tumors that includes a pervasive infiltration of immunosuppressive (M2) macrophages. Nab-pa...

journal_title：Cancer immunology research

authors： Cullis J,Siolas D,Avanzi A,Barui S,Maitra A,Bar-Sagi D

更新日期：2017-03-01 00:00:00

abstract：:The TNF receptor family member OX40 promotes activation and proliferation of T cells, which fuels efforts to modulate this immune checkpoint to reinforce antitumor immunity. Besides T cells, NK cells are a second cytotoxic lymphocyte subset that contributes to antitumor immunity, particularly in leukemia. Accordingly,...

journal_title：Cancer immunology research

authors： Nuebling T,Schumacher CE,Hofmann M,Hagelstein I,Schmiedel BJ,Maurer S,Federmann B,Rothfelder K,Roerden M,Dörfel D,Schneider P,Jung G,Salih HR

更新日期：2018-02-01 00:00:00

abstract：:Natural killer cell (NKc)-based therapies offer promising outcomes in patients with tumors, but they could improve with appropriate selection of donors and optimization of methods to expand NKcs in vitro Education through licensing interactions of inhibitory killer cell immunoglobulin-like receptors (iKIR) and NKG2A w...

journal_title：Cancer immunology research

authors： Guillamón CF,Martínez-Sánchez MV,Gimeno L,Mrowiec A,Martínez-García J,Server-Pastor G,Martínez-Escribano J,Torroba A,Ferri B,Abellán D,Campillo JA,Legaz I,López-Álvarez MR,Moya-Quiles MR,Muro M,Minguela A

更新日期：2018-12-01 00:00:00

abstract：:On September 25-28, 2016, in New York City, the Second International Cancer Immunotherapy Conference was cohosted by the Cancer Research Institute, the American Association for Cancer Research, the Association for Cancer Immunotherapy, and the European Academy of Tumor Immunology. This exciting conference brought toge...

journal_title：Cancer immunology research

authors： Brodsky AN,Hubbard-Lucey VM

更新日期：2016-12-01 00:00:00